期刊文献+

针对结核分枝杆菌潜伏感染的DNA疫苗V569免疫原性及保护性的初步研究 被引量:3

Immunogenicity and protective results of DNA vaccine V569 against latent tuberculosis infection in animal models
下载PDF
导出
摘要 为研究针对结核分枝杆菌潜伏感染的DNA疫苗,基于质粒A39构建了p-VAX1-Ag85B-Rv3425-Rv2029c-PPE26(V569)质粒DNA,并对其免疫原性及保护性进行初步研究。免疫性评价试验共分6组:PBS、p-VAX1-Ag85B(A)、p-VAX1-Ag85B-Rv3425(A3)、A39、V569和BCG,采用左后腿肌内注射C57BL/6小鼠,用流式细胞术和酶联免疫吸附试验(enzyme linked immunosorbent assay,ELISA)分别检测细胞免疫和体液免疫水平;构建斑马鱼-海分枝杆菌潜伏感染模型,将PBS、A、A3、A39、BCG、V569分别通过腹腔注射免疫斑马鱼后,每日注射地塞米松10ug诱导海分枝杆菌复发感染,对斑马鱼肝脏进行菌落计数并绘制生存曲线。结果显示,与BCG组相比,V569能引发实验小鼠强烈的细胞免疫反应(IFN-γ高水平分泌),外周血CD4+/CD8+T细胞比例明显增加。在斑马鱼-海分枝杆菌潜伏感染复发模型中,与BCG免疫组相比,V569免疫斑马鱼后可显著减少其肝脏中海分枝杆菌数量,斑马鱼存活情况得到显著改善,表明V569 DNA疫苗可能是一种抗结核潜伏感染的候选DNA疫苗。 We constructed the DNA vaccine Ag85B-Rv3425-Rv2029c-PPE26(V569)plasmid based on p-VAX1-Ag85B-Rv3425-Rv2029c(A39)and evaluated its immunogenicity in mice.The levels of cellular immunity and humoral immunity against PBS,BCG,p-VAX1-Ag85B(A),p-VAX1-Ag85B-Rv3425(A3),A39 and V569 were detected by enzyme-linked immunosorbent assay(ELISA)and flow cytometry after vaccination in mice.We found that V569 could trigger stronger Th1 immune response by augmenting the secretion of IFN-γand significantly improve the CD4+/CD8+T cell ratio in immunized mice compared to BCG.In addition,we evaluated the V569 as post-exposure DNA vaccine and found that it reduced bacterial burdens upon reactivation compared to BCG.The protection of V569 against latent TB infection was determined by zebrafish-Mycobacterium marinum latent infection model.In conclusion,V569 DNA vaccine may be a potential candidate DNA vaccine against latent tuberculosis infection.
作者 粟海波 刘梓健 周洋洋 彭宝洲 龚青 SU Haibo;LIU Zijian;ZHOU Yangyang;PENG Baozhou;GONG Qing(GMU-GIBH Joint School of Life Sciences,Guangzhou Medical University,Guangzhou 511436,China)
出处 《微生物与感染》 2019年第5期289-296,共8页 Journal of Microbes and Infections
基金 广东省高校优秀青年创新人才培养计划资助项目(2016KQNCX141) 广州市科技计划一般项目(201804010317) 广东省自然科学基金面上项目(2018A030313560)
关键词 PPE26 结核潜伏感染 DNA疫苗 Rv3425 Th1型细胞免疫反应 PPE26 Latent tuberculosis infection DNA vaccine Rv3425 Th1 type cellular immune response
  • 相关文献

参考文献2

二级参考文献53

  • 1Kaufmann SH. Future vaccination strategies against tuberculosis., thinking outside the box [J]. Immunity, 2010, 33(4) : 567-577.
  • 2Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P. A multistage tuberculosis vaccine that confers efficient protection before and after exposure [J]. Nat Med, 2011, 17(2): 189-194.
  • 3Lin MY, Ottenhoff TH. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection [J]. Biol Chem, 2008, 389(5) : 497-511.
  • 4Ahmad Z, Sharma S, Khuller GK. The potential of azolc antifungals against latent/persistent tuberculosis [J]. FEMS Microbiol Lett, 2006, 258(2): 200-203.
  • 5Hamborg M, Kramer R, Schant6 CE, Agger EM, Christensen D, Jorgensen L, Foged C, Middaugh CR. The physical stability of the recombinant tuberculosis fusion antigens hl and h56 [J]. J Pharm Sci, 2013, 102(10): 3567-3578.
  • 6Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, Bigbce C, Bigbee M, Milk L, Gideon HP, Rodgers M, Cochran C, Guinn KM, Sherman DR, Klein E, Janssen C, Flynn JL, Andersen P. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection [J]. J Clin Invest, 2012, 122(1 ): 303- 314.
  • 7Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, Coler RN, Reed SG. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug- resistant Mycobacterium tuberculosis [J]. Sci Transl Med, 2010, 2(53): 53ra74.
  • 8Vilaplana C, Gil O, Cficeres N, Pinto S, Diaz J, Cardona PJ. Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis [J]. PLoS One, 2011, 6(5): e20404.
  • 9Vilaplana C, Montan6 E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J. Double- blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI [J]. Vaccine, 2010, 28(4): 1106-1116.
  • 10Domingo M, Gil O, Serrano E, Guirado E, Nofrarias M, Grassa M, Coceres N, P6rez B, Vilaplana C, Cardona P3. Effectiveness and safety of a treatment regimen based on isoniazid plus vaccination with Myeobacterium tuberculosis cells' fragments: field-study with naturally Mycobacterium caprae-infected goats F Jl. Scand ,i Immunol, 2009, 69 (6) : 500-507.

共引文献10

同被引文献46

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部